The primary benefit of ADCs lies in their targeted approach. By selectively binding to cancer cells, ADCs can reduce the systemic toxicity commonly associated with traditional chemotherapy. This targeted delivery allows for higher doses of the cytotoxic agent to be used, potentially improving efficacy. Additionally, the use of monoclonal antibodies enables the exploitation of various tumor-specific antigens, offering the possibility of personalized therapy.
